Chaturvedi P, Pratta M, Steplewski K, Connor J, Kumar S
Microbial, Musculoskeletal, and Proliferative Diseases, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA.
Arthritis Rheum. 2006 Nov;54(11):3513-22. doi: 10.1002/art.22170.
To evaluate the expression and function of the orphan nuclear receptor Rev-ErbAalpha in articular cartilage and to investigate its role in osteoarthritis (OA).
Expression of Rev-ErbAalpha was analyzed at both the messenger RNA and protein levels in human and bovine articular cartilage and chondrocytes by real-time polymerase chain reaction (TaqMan) and immunocytochemical techniques. The effects of cartilage catabolic and anabolic agents on the expression of Rev-ErbAalpha were evaluated by TaqMan analysis. Overexpression was achieved by either adenoviral transduction or treatment with a peroxisome proliferator-activated receptor alpha agonist, whereas expression was suppressed by antisense oligonucleotides.
Among the 48 known nuclear receptors, Rev-ErbAalpha was found to be the most highly expressed in OA cartilage. It is known to function as a transcription repressor. Treatment of articular chondrocytes with known catabolic agents resulted in the induction of Rev-ErbAalpha, whereas stimulation with anabolic agents led to a decrease in expression. Overexpression of the nuclear receptor was associated with an increase in the expression of matrix-degrading enzymes such as matrix metalloproteinase 13 and aggrecanase. In contrast, a decrease in Rev-ErbAalpha expression led to a concomitant reduction in the activity of matrix-degrading enzymes.
This study is the first to demonstrate that Rev-ErbAalpha is highly expressed in OA articular chondrocytes and that its expression is modulated by known cartilage catabolic and anabolic stimuli. We also demonstrated that modulation of Rev-ErbAalpha expression in chondrocytes may be a novel means of regulating the expression and production of multiple matrix-degrading enzymes. These observations suggest that Rev-ErbAalpha may be a novel therapeutic target for OA.
评估孤儿核受体Rev-ErbAα在关节软骨中的表达及功能,并研究其在骨关节炎(OA)中的作用。
采用实时聚合酶链反应(TaqMan)和免疫细胞化学技术,在信使核糖核酸和蛋白质水平分析Rev-ErbAα在人及牛关节软骨和软骨细胞中的表达。通过TaqMan分析评估软骨分解代谢和合成代谢因子对Rev-ErbAα表达的影响。通过腺病毒转导或用过氧化物酶体增殖物激活受体α激动剂处理实现过表达,而用反义寡核苷酸抑制表达。
在48种已知核受体中,发现Rev-ErbAα在OA软骨中表达最高。已知其作为转录抑制因子发挥作用。用已知分解代谢因子处理关节软骨细胞导致Rev-ErbAα诱导表达,而用合成代谢因子刺激则导致表达降低。核受体的过表达与基质金属蛋白酶13和聚集蛋白聚糖酶等基质降解酶的表达增加相关。相反,Rev-ErbAα表达降低导致基质降解酶活性随之降低。
本研究首次证明Rev-ErbAα在OA关节软骨细胞中高表达,且其表达受已知软骨分解代谢和合成代谢刺激的调节。我们还证明调节软骨细胞中Rev-ErbAα的表达可能是调节多种基质降解酶表达和产生的新方法。这些观察结果表明Rev-ErbAα可能是OA的新治疗靶点。